Neopath (NPTH) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neopath (NPTH)

NPTH 0.000600

0.0%

Mar 7 3:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Cytotekk who wrote (132)	5/6/1998 12:32:00 PM
From: Sigmund	Read Replies (1) of 178

But to be correct one has to compare AutoPap as a primary screener as compared to a secondary screener. Secondary screening has been approved for some time and the laboratories have either bought it or rejected it. Now it is likely that the first sign of acceptance by laboratories will be those with secondary screening upgrading to primary screening. Here is where I question the economics. What is your understanding as to how AutoPap works as a secondary screener? Does it screen all the slides and recommend 15% for further manual review or does it itself do the rereads of a 15% sample?

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next